Business, energy, technology, markets and global industry news from Business News Today

Pharma & Biotech

PharmaDeviceNews Pharma & Biotech
Pharma & Biotech

Why TG Therapeutics’ BRIUMVI data could open a new treatment path in myasthenia gravis

Find out how TG Therapeutics’ BRIUMVI data could shape a new maintenance strategy in myasthenia gravis treatment.

Read More
Representative image: Cancer research team reviews tumor data as Harbour BioMed’s HBM7004 advances toward clinical testing for advanced solid tumors.
Pharma & Biotech

Harbour BioMed’s HBM7004 China IND acceptance sharpens the race for B7-H4 cancer targets

Find out how Harbour BioMed’s HBM7004 China IND acceptance could reshape B7-H4 solid tumor immunotherapy development.

Read More
Representative image: A paediatric audiology assessment highlights the clinical focus behind Sensorion’s SENS-601 gene therapy program for GJB2-related hearing loss.
Pharma & Biotech

Sensorion’s SENS-601 strategy signals a sharper bet on larger genetic hearing loss markets

Find out how Sensorion’s SENS-601 regulatory push could reshape GJB2 hearing loss gene therapy and clinical strategy.

Read More
Representative image: A clinician reviews spinal imaging as Zetagen Therapeutics’ ZetaMet Phase 2a data highlights investigational progress in treating metastatic breast cancer patients with lytic bone lesions.
Pharma & Biotech

Can Zetagen’s ZetaMet Phase 2a data change how metastatic breast cancer bone lesions are treated?

Find out how Zetagen’s ZetaMet Phase 2a data may reshape treatment of metastatic breast cancer bone lesions.

Read More
Pharma & Biotech

Why Lilly’s expanded Ebglyss label could reset dosing expectations in atopic dermatitis biologics

Ebglyss gains an every-eight-week FDA maintenance option, raising new questions for atopic dermatitis biologic competition.

Read More
Representative image of CNS drug development and neuroscience research, highlighting Enveric Biosciences’ EB-003 push toward clinical-stage neuroplastogen testing.
Pharma & Biotech

Enveric Biosciences’ EB-003 push highlights the next battle in neuroplastogen drug development

Read how Enveric Biosciences’ EB-003 investor push reshapes CNS biotech risk, regulation and clinical strategy.

Read More
Pharma & Biotech

Entyvio pediatric filing puts Takeda at the centre of the next IBD treatment debate

Find out how Takeda’s pediatric Entyvio review could change biologic treatment choices in ulcerative colitis and Crohn’s disease.

Read More
Representative image: A clinician reviews spinal imaging for chronic low back pain as Vertanical’s Exilby approval highlights the growing push for regulated non-opioid pain treatments in Europe.
Pharma & Biotech

Vertanical’s Exilby approval puts cannabis-derived pain drugs under a brighter spotlight

Exilby’s German approval gives chronic pain medicine a rare non-opioid test case. Can Vertanical convert data into adoption?

Read More
Representative image: GSK’s $10.6 billion Nuvalent deal puts precision lung cancer therapies in focus as Big Pharma races to secure late-stage oncology assets.
Pharma & Biotech

Why GSK is paying $10.6bn for Nuvalent as targeted lung cancer drugs near FDA decisions

GSK is betting $10.6B on Nuvalent’s lung cancer drugs. The payoff now depends on FDA decisions, labels and oncology launch execution.

Read More
Representative image of oncology researchers reviewing molecular data in a biotechnology lab, reflecting Johnson & Johnson’s Firefly Bio deal and the race to advance degrader antibody conjugates for hard-to-treat solid tumors.
Pharma & Biotech

Why Johnson & Johnson is paying $1bn for Firefly Bio’s cancer drug platform

Johnson & Johnson is chasing the next cancer drug platform. Firefly Bio adds promise, but clinical proof remains the real test.

Read More